VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions (VST100)

VasoStar

Status

Enrolling

Conditions

Chronic Angina

Chronic Total Occlusion of Coronary Artery

Treatments

Device: VasoStar guidewire system

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT06193954

VST100

Details and patient eligibility

About

The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.

Full description

This Early Feasibility Study (EFS) is proposed to evaluate the initial safety and efficacy of the VasoStar guidewire system to cross complex coronary vascular lesions in non-tortuous arterial segments which are resistant to crossing with a traditional interventional guidewire.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female, over 18 years of age, presenting with at least one ischemia inducing lesion in a native coronary artery that is refractory to standard guidewire crossing. Chronic total occlusion (CTO) is defined as 100% coronary blockage for over a 3-month duration documented either by prior catheterization or by clinical evaluation
Suitable candidate for non-emergent, coronary angioplasty
Documented de-novo or restenotic coronary chronic total occlusion defined as a lesion with TIMI 0 flow for at least 90 days refractory to conventional guidewire crossing
Left ventricle ejection fraction > 20% within the last 12 months.
For antegrade chronic total occlusion procedures, activated clotting time (ACT) should be > 300 sec
Chronic total occlusion in a non-tortuous arterial segment
Voluntarily sign a Patient Informed Consent Form specific to the study.
Physically and mentally willing to comply with all study requirements.

Exclusion criteria

Successful target lesion crossing with a conventional wire system prior to enrollment
Prisoners.
Pregnancy
Patient has an active implantable.
Extensive dissection created by refractory guidewire
Severe ongoing congestive heart failure (New York Heart Association Class IV symptoms)
Active infection
Uncontrolled Hypertension (Systolic blood pressure > 180 mm) at the time of the procedure
History of severe reaction to contrast media
Recent myocardial infarction (within 2 weeks)
In-stent target lesion
Severe cerebrovascular disease including history of prior stroke or transient ischemic attack within 1 month at the time of the procedure
Saphenous vein graft (SVG) chronic total occlusion or an in-stent chronic total occlusion
Short life expectancy due to other illnesses such as cancer or pulmonary, hepatic or renal disease
Participation in another investigational protocol at the time of the procedure